The Australian Competition Authority accepts a proposed merger between two pharmaceutical companies despite concerns of a significant reduction in competition in the supply of the products (Mylan / Upjohn)

On 10 September 2020, the Australian Competition and Consumer Commission ("ACCC") decided to not oppose Mylan NV’s ("Mylan") proposed merger with Pfizer’s Upjohn Inc division ("Upjohn"), despite concerns that competition in the supply of pharmaceutical products to treat cardiovascular conditions and glaucoma would significantly reduce. The ACCC's competition concerns were resolved by the parties providing court-enforceable undertakings to

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Ashurst (Sydney)

Quotation

Ross Zaurrini, The Australian Competition Authority accepts a proposed merger between two pharmaceutical companies despite concerns of a significant reduction in competition in the supply of the products (Mylan / Upjohn), 10 September 2020, e-Competitions September 2020, Art. N° 96965

Visites 120

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues